<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03600519</url>
  </required_header>
  <id_info>
    <org_study_id>BNZ-0060-18</org_study_id>
    <nct_id>NCT03600519</nct_id>
  </id_info>
  <brief_title>Retinal Imaging Using NOTAL-OCT V2.5</brief_title>
  <official_title>Retinal Imaging Using NOTAL-OCT V2.5</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Notal Vision Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Notal Vision Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Primary objectives:&#xD;
&#xD;
      To compare between retinal measurements, done by the NOTAL-OCT V2.5 device and a commercial&#xD;
      OCT.&#xD;
&#xD;
      Secondary objectives:&#xD;
&#xD;
        1. To evaluate the level of agreement between the NOTAL-OCT V2.5 and a commercial OCT in&#xD;
           the presence of fluid as identified in the OCT images, in the central 10 degrees of the&#xD;
           macula.&#xD;
&#xD;
        2. To evaluate the repeatability of the NOTAL-OCT V2.5&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Study population:&#xD;
&#xD;
        1. AMD population - intermediate and advanced AMD (with active and nonactive CNV)&#xD;
&#xD;
        2. DR population. Patient with and without DME&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">July 22, 2018</start_date>
  <completion_date type="Actual">January 1, 2020</completion_date>
  <primary_completion_date type="Actual">February 18, 2019</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>The level of agreement between NOTAL-OCT V2.5 and commercial OCT in detecting fluid</measure>
    <time_frame>less than an hour</time_frame>
    <description>measurements of retinal thickness.</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">87</enrollment>
  <condition>AMD</condition>
  <arm_group>
    <arm_group_label>AMD Patients</arm_group_label>
    <description>OCT scan</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>NOTAL OCT V2.5</intervention_name>
    <description>AMD Patients</description>
    <arm_group_label>AMD Patients</arm_group_label>
    <other_name>OCT scan</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        MAD patients&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        1. Inclusion Criteria:&#xD;
&#xD;
             a- Ability and agreement to give informed consent (IC) b -Diagnosis of AMD or DR in SE&#xD;
             by OCT c- Ability to undergo OCT scans d- VA of 20/400 (6/120) or better in SE&#xD;
&#xD;
          2. Exclusion Criteria:&#xD;
&#xD;
               1. AMD and DR in the same SE&#xD;
&#xD;
               2. Evidence of macular disease other than AMD or DME in SE&#xD;
&#xD;
               3. Patient with dilated eye(s)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Bnei Zion</name>
      <address>
        <city>Haifa</city>
        <zip>3339123</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Israel</country>
  </location_countries>
  <verification_date>October 2020</verification_date>
  <study_first_submitted>July 17, 2018</study_first_submitted>
  <study_first_submitted_qc>July 17, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">July 26, 2018</study_first_posted>
  <last_update_submitted>November 11, 2020</last_update_submitted>
  <last_update_submitted_qc>November 11, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">November 13, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

